These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9426715)

  • 1. Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon.
    Gebrosky NP; Koukol S; Nseyo UO; Carpenter C; Lamm DL
    Urology; 1997 Dec; 50(6):863-7; discussion 867-8. PubMed ID: 9426715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
    J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
    Pazdur R; Ajani JA; Patt YZ; Gomez J; Bready B; Levin B
    Cancer; 1993 Feb; 71(4):1214-8. PubMed ID: 8435795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.
    Ragnhammar P; Blomgren H; Edler D; Lundell G; Magnusson I; Sonnenfeld T
    Eur J Cancer; 1995; 31A(3):315-20. PubMed ID: 7786594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
    J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
    Ravaud A; Audhuy B; Gomez F; Escudier B; Lesimple T; Chevreau C; Douillard JY; Caty A; Geoffrois L; Ferrero JM; Linassier C; Drevon M; Négrier S
    J Clin Oncol; 1998 Aug; 16(8):2728-32. PubMed ID: 9704724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
    Fujinami K; Ikeda I; Miura T; Kondo I
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1689-91. PubMed ID: 8886046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
    Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
    J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
    Atzpodien J; Kirchner H; Illiger HJ; Metzner B; Ukena D; Schott H; Funke PJ; Gramatzki M; Jürgenson S; Wandert T; Patzelt T; Reitz M
    Br J Cancer; 2001 Oct; 85(8):1130-6. PubMed ID: 11710825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
    Padrik P; Leppik K; Arak A
    Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Ryan CW; Vogelzang NJ; Stadler WM
    Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
    John WJ; Neefe JR; Macdonald JS; Cantrell J; Smith M
    Cancer; 1993 Dec; 72(11):3191-5. PubMed ID: 8242541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.